Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2024-2030
Description
Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2024-2030
The Pulmonary Drugs Market size was estimated at USD 79.35 billion in 2023 and expected to reach USD 86.14 billion in 2024, at a CAGR 8.03% to reach USD 136.27 billion by 2030.
The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.
Regional Insights
The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Pulmonary Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
- Improvements in reimbursements and favorable government approvals for pulmonary drugs
- Market Restraints
- Increasing recall of drugs used for pulmonary conditions
- Market Opportunities
- Development of new biologics and targeted drugs for pulmonary disease treatment
- Advancements in inhaled drug delivery therapies and technologies
- Market Challenges
- Limitations associated with improper drug delivery and development of drug resistance
- Market Segmentation Analysis
- Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
- Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
- Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
- Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
- End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pulmonary Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of their Phase 2a trial (NCT05483907). This trial aims to evaluate the efficacy, safety, and tolerability of BBT-877 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). These promising results indicate the company’s BBT-877 has the potential to be an effective treatment for IPF when administered at the appropriate dose and schedule.
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
Bristol Myers Squibb has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for its potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, BMS-986278. This breakthrough therapy is intended for the treatment of progressive pulmonary fibrosis (PPF). BMS-986278 was well tolerated, with adverse event rates similar to placebo and low discontinuation rates. The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of medicines for serious or life-threatening diseases.
Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
Aiolos Bio secured USD 245 million in Series A funding from prominent investors including Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners, Sofinnova Investments, and RA Capital Management. The funding was allocated towards Phase 2 clinical trials for Aiolos Bio's lead drug candidate, AIO-001 as a treatment for moderate-to-severe asthma patients.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pulmonary Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.
Market Segmentation & Coverage
This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Drug Class
- Anti-Cholinergic Agents
- Anti-Leukotrienes
- Antihistamines
- Beta-2 Agonists
- Combination Drugs
- Monoclonal Antibodies
- Oral & Inhaled Corticosteroids
- Indication
- Allergic Rhinitis
- Asthma
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Pulmonary Arterial Hypertension
- Drug Type
- Generic Drugs
- Prescription Drugs
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- End-User
- Homecare
- Hospitals
- Specialty Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
- 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
- 5.1.2. Restraints
- 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
- 5.1.3. Opportunities
- 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
- 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
- 5.1.4. Challenges
- 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
- 5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
- 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
- 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
- 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
- 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
- 5.3. Market Trend Analysis
- 5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
- 5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government’s financial support for drug commercialization
- 5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Pulmonary Drugs Market, by Drug Class
- 6.1. Introduction
- 6.2. Anti-Cholinergic Agents
- 6.3. Anti-Leukotrienes
- 6.4. Antihistamines
- 6.5. Beta-2 Agonists
- 6.6. Combination Drugs
- 6.7. Monoclonal Antibodies
- 6.8. Oral & Inhaled Corticosteroids
- 7. Pulmonary Drugs Market, by Indication
- 7.1. Introduction
- 7.2. Allergic Rhinitis
- 7.3. Asthma
- 7.4. Chronic Obstructive Pulmonary Disease
- 7.5. Cystic Fibrosis
- 7.6. Pulmonary Arterial Hypertension
- 8. Pulmonary Drugs Market, by Drug Type
- 8.1. Introduction
- 8.2. Generic Drugs
- 8.3. Prescription Drugs
- 9. Pulmonary Drugs Market, by Distribution Channel
- 9.1. Introduction
- 9.2. Hospital Pharmacies
- 9.3. Online Pharmacies
- 9.4. Retail Pharmacies
- 10. Pulmonary Drugs Market, by End-User
- 10.1. Introduction
- 10.2. Homecare
- 10.3. Hospitals
- 10.4. Specialty Clinics
- 11. Americas Pulmonary Drugs Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Pulmonary Drugs Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Pulmonary Drugs Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2023
- 14.2. FPNV Positioning Matrix, 2023
- 14.3. Competitive Scenario Analysis
- 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
- 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
- 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
- 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
- 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
- 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
- 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
- 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
- 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
- 14.3.10. US FDA Approves GSK’s Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
- 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
- 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
